The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.
EU’s CHMP Recommends Nivolumab Combo Approval in Urothelial Carcinoma
Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.
Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
MRD Negativity Status Following Surgery Confers Survival in MIBC
Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.
Emerging Immunotherapy Approaches For Urothelial Cancer
Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.
Enfortumab Vedotin Combo Earns Priority Review in China for Bladder Cancer
Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.
FDA Approves First-line Nivolumab Combo for Urothelial Carcinoma
Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.